Overdose of pegfilgrastim: case report
Background Pegfilgrastim is a G-CSF that can be administered in a single dose 24 h after each cycle of chemotherapy. Case 59 years-old man with a stage III-B peripheral T lymphoma with CD4 expression. Dose-dense chemotherapy was started with CHOP-14 combined with pegfilgrastim as primary prophylaxis. An error in the dispensing system meant that the patient received pegfilgrastim for 4 consecutive days. He remained under observation in hospital. During the 3 days after the last dose of pegfilgrastim, the patient remained stable, with no remarkable symptoms or associated laboratory abnormalities, and was discharged. Conclusion The case we describe and the available literature lead us to suggest close monitoring as the main measure to be adopted when treating a patient for pegfilgrastim overdose.
Conflicts of interest
The authors have no conflict of interest to declare.
- 2.Neulasta® (pegfilgrastim) Summary of Product Characteristics (Spanish). Accessed Aug 27, 2010. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000420/WC500025945.pdf.